Abeona Therapeutics Inc. (NASDAQ:ABEO) CEO Sells $406,801.20 in Stock

Abeona Therapeutics Inc. (NASDAQ:ABEO - Get Free Report) CEO Vishwas Seshadri sold 69,420 shares of the business's stock in a transaction dated Wednesday, July 9th. The stock was sold at an average price of $5.86, for a total transaction of $406,801.20. Following the completion of the transaction, the chief executive officer directly owned 1,234,341 shares of the company's stock, valued at approximately $7,233,238.26. This represents a 5.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Vishwas Seshadri also recently made the following trade(s):

• On Friday, June 6th, Vishwas Seshadri sold 50,676 shares of Abeona Therapeutics stock. The stock was sold at an average price of $6.76, for a total transaction of $342,569.76.

Abeona Therapeutics Trading Down 1.9%

NASDAQ ABEO traded down $0.11 during trading on Friday, reaching $5.74. 774,254 shares of the stock traded hands, compared to its average volume of 701,588. The firm has a market cap of $293.64 million, a price-to-earnings ratio of -4.52 and a beta of 1.51. The stock's 50-day moving average price is $6.01 and its 200 day moving average price is $5.57. The company has a quick ratio of 4.90, a current ratio of 4.90 and a debt-to-equity ratio of 0.27. Abeona Therapeutics Inc. has a fifty-two week low of $3.93 and a fifty-two week high of $7.32.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last issued its quarterly earnings data on Thursday, May 15th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.35) by $0.11. Analysts predict that Abeona Therapeutics Inc. will post -1.16 EPS for the current year.

Institutional Investors Weigh In On Abeona Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. OMERS ADMINISTRATION Corp raised its holdings in shares of Abeona Therapeutics by 11.0% during the first quarter. OMERS ADMINISTRATION Corp now owns 72,200 shares of the biopharmaceutical company's stock worth $344,000 after acquiring an additional 7,155 shares during the period. Twinbeech Capital LP acquired a new stake in shares of Abeona Therapeutics during the fourth quarter worth $58,000. Northern Trust Corp raised its holdings in shares of Abeona Therapeutics by 6.6% during the fourth quarter. Northern Trust Corp now owns 184,929 shares of the biopharmaceutical company's stock worth $1,030,000 after acquiring an additional 11,478 shares during the period. Squarepoint Ops LLC acquired a new stake in shares of Abeona Therapeutics during the fourth quarter worth $67,000. Finally, Cannon Global Investment Management LLC acquired a new stake in shares of Abeona Therapeutics during the first quarter worth $67,000. 80.56% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have recently commented on ABEO shares. Oppenheimer started coverage on shares of Abeona Therapeutics in a research report on Monday, June 2nd. They set an "outperform" rating and a $19.00 price target for the company. Alliance Global Partners reiterated a "buy" rating on shares of Abeona Therapeutics in a research report on Thursday, May 15th. Stifel Nicolaus decreased their price objective on shares of Abeona Therapeutics from $21.00 to $20.00 and set a "buy" rating for the company in a report on Friday, May 16th. HC Wainwright boosted their price objective on shares of Abeona Therapeutics from $15.00 to $20.00 and gave the company a "buy" rating in a report on Wednesday, April 30th. Finally, Wall Street Zen cut shares of Abeona Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 15th. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $19.25.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.